Navigation Links
Oramed's Platform Technology in Oral Delivery of Proteins Receives Patent in Russia

JERUSALEM, September 17, 2013 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (, a developer of oral drug delivery systems, announced today that it has been granted a patent from Russia's Federal Service for Intellectual Property, Patents and Trademarks (ROSPATENT) for the Company's invention, titled "Methods and Compositions for Oral Administrations of Proteins." The patent covers a core concept of the Company's technology for the oral delivery of drugs currently delivered via injection. Oral delivery can greatly improve patient compliance and outcomes.

This patent has also been granted in New Zealand, South Africa and China. Oramed's intellectual property portfolio now consists of nine issued patents and 26 patents pending.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's technology is based on over 30 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently initiating Phase 2 clinical trials on patients with type 2 diabetes (T2DM) under an Investigational New Drug application with the U.S. Food and Drug Administration, and with its oral exenatide capsule (ORMD-0901; a GLP-1 analog), with trials on healthy volunteers (Phase 1b) and T2DM patients (Phase 2a) underway. Oramed is also moving forward with clinical trials of ORMD-0801 for the treatment of type 1 diabetes. The company's corporate and R&D headquarters are based in Jerusalem.

For more information, the content of which is not part of this press release, please visit

Forward-looking statements: This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss our clinical trials, revolutionizing the treatment of diabetes with our products or the impact oral delivery can have on patient compliance and outcomes. These forward-looking statements and their implications are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and final that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission.

Company Contact:
Oramed Pharmaceuticals
Aviva Sherman
Office: +972-2-566-0001
Mobile: +972-54-792-4438

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Guangzhous Sun Yat-sen University Cancer Center Debuts MOSAIQ in the Chinese Platform
2. Effie Toshav Joins Fenwick - Broadens Life Sciences Service Platform
3. Simbionix Releases Two New Platforms at the Upcoming DDW and AUA Events
4. Mylan Sponsors Drug Store News and Pharmacist Society to Provide a New Business Networking Platform for Pharmacy Schools and Students
5. Aushon to Launch New Multiplex Immunoassay Platform
6. ZyDoc Selects Health Fidelitys REVEAL™ Natural Language Processing (NLP) Platform to Accelerate Time to Value for its MediSapien Web Services
7. iBio Announces Important Expansion of its Intellectual Property Portfolio: Allowance of Patent for Anthrax Vaccines and Further Application of Modulator Platform
8. Biosimilars in Emerging Economies - Advanced Recombinant Technology Platforms and Low Cost Manufacturing Put India and China at a Strategic Advantage in Biosimilar Production
9. WaferGen Bio-systems Launches MyDesign - Setting a New Standard in Flexibility with an Open Format High-Throughput qPCR Platform
10. ACR Chooses NDSC to Deliver ACR Select, a Comprehensive EHR-Enabled Medical Imaging Clinical Decision Support Platform
11. ResearchMoz.US: Direct to Consumer (DTC) Advertising in Pharmaceuticals - Shift From Traditional Mass-Media Platforms Towards Personalization via Online and Social Media- Market Research Report
Post Your Comments:
(Date:11/25/2015)... DUBLIN , November 25, 2015 ... has announced the addition of the  ... 2015-2019"  report to their offering.  ... announced the addition of the  "Global ...  report to their offering.  ...
(Date:11/24/2015)... 24, 2015  Array BioPharma Inc. (Nasdaq: ... Officer, Ron Squarer , will present at ... York.  The public is welcome to participate in ... BioPharma website.Event:Piper Jaffray Annual Healthcare ConferencePresenter:  , Ron ... 2015Time:1:30 p.m. Eastern Time Webcast: , ...
(Date:11/24/2015)... NEWS, Va. , Nov. 24, 2015  DILON ... they have signed an agreement for DILON to distribute ... geographies across the globe. The signing of this distribution agreement ... Discovery NM750b Molecular Breast Imaging system and is considered ... to provide better healthcare solutions for clinicians and their ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... 2015 , ... The McHenry County law firm of Botto Gilbert Lancaster, ... Francisco J. Botto and Alex C. Wimmer. Attorneys Botto and Wimmer represented the claimant ... (2d) 130884WC. , According to court documents, Adcock testified that on May 10, 2010 ...
(Date:11/25/2015)... ... November 25, 2015 , ... Beddit® has launched a new Android ... The new app features a more intuitive SleepScore™ that rates sleep quality on a ... The SleepScore is created by a proprietary algorithm. Beddit analyzes the data to provide ...
(Date:11/25/2015)... ... ... Today, Mothers Against Drunk Driving (MADD) learned that the number ... first time since 2011. In 2014, there were 9,967 fatalities involving an alcohol impaired ... Highway Traffic Safety Administration (NHTSA), 32,675 people were killed in traffic crashes in 2014. ...
(Date:11/25/2015)... ... 2015 , ... Privately owned Contract Development and Manufacturing Organization ... current state of the art research, development and manufacturing facility outside of Fort ... capacity as well as to support its clients’ growing research and development and ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... has focused on providing comprehensive solutions involving adult stem cell therapies to patients ... officially deemed the “Regenestem” name as a Registered Trademark (RTM). , Organizations are ...
Breaking Medicine News(10 mins):